Tax-withholding share disposition by ANI Pharmaceuticals (ANIP) executive

Rhea-AI Filing Summary

ANI Pharmaceuticals executive Christopher Mutz, Head of Rare Disease, reported a tax-withholding disposition of company stock related to equity compensation. On February 11, 2026, 4,546 shares of ANI Pharmaceuticals common stock were withheld at $76.25 per share to cover taxes.

This withholding was tied to the vesting of 11,578 performance stock units previously granted on April 6, 2023 and is exempt under Rule 16(b)-3. After this transaction, Mutz directly holds 102,771 shares of ANI Pharmaceuticals common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mutz Christopher

Role HEAD OF RARE DISEASE

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	4,546	$76.25	$347K

Holdings After Transaction: Common Stock — 102,771 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mutz Christopher

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	HEAD OF RARE DISEASE

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		F(1)		4,546	D	$76.25	102,771	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 11,578 performance stock units, the grant of which was previously reported on April 6, 2023.

Remarks:

	/s/ Christopher Mutz, by attorney-in-fact Meredith W. Cook	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ANI Pharmaceuticals (ANIP) report for Christopher Mutz?

ANI Pharmaceuticals reported a tax-withholding share disposition for executive Christopher Mutz. On February 11, 2026, 4,546 common shares were withheld at $76.25 each to cover taxes arising from the vesting of previously granted performance stock units.

Was the ANI Pharmaceuticals (ANIP) Form 4 transaction a stock sale by Christopher Mutz?

No, the Form 4 shows a tax-withholding disposition, not an open-market sale. Shares were withheld by the issuer to satisfy tax obligations triggered by the vesting of performance stock units, and are reported under transaction code F on the form.

How many ANI Pharmaceuticals (ANIP) shares were withheld for taxes in this Form 4?

A total of 4,546 ANI Pharmaceuticals common shares were withheld for taxes. The withholding occurred at a price of $76.25 per share, in connection with the vesting of 11,578 performance stock units previously granted to executive Christopher Mutz.

How many ANI Pharmaceuticals (ANIP) shares does Christopher Mutz own after the reported transaction?

After the transaction, Christopher Mutz beneficially owns 102,771 common shares. This post-transaction figure reflects his direct holdings following the withholding of 4,546 shares for tax purposes tied to vesting performance stock units.

What equity award vesting triggered the ANI Pharmaceuticals (ANIP) tax withholding?

The tax withholding was triggered by the vesting of 11,578 performance stock units. These units were originally granted on April 6, 2023, and their vesting led to shares being withheld to cover associated tax liabilities under Rule 16(b)-3.

What does transaction code F mean in the ANI Pharmaceuticals (ANIP) Form 4?

Transaction code F indicates a payment of tax liability or exercise price using securities. In this filing, it shows issuer share withholding to satisfy taxes from the vesting of performance stock units, rather than a discretionary market purchase or sale by the insider.